Cancer
Showing of 44 results
University Hospitals Physician-scientist, Linda Cummings, Selected for American Gastroenterological Association Pilot Research Award
Research will address growing problem of antimicrobial resistance in eradicating Helicobacter Pylori (H. pylori), a bacterial infection that increases the risk of gastric cancer and peptic ulcer disease.
International Harrington Prize Awarded to Dr. Arlene Sharpe
2024 Harrington Prize for Innovation in Medicine Recognizes Pioneering Work in Immunology.
Novel Oral Hormone Therapy Shows Promising Results for Prostate Cancer Treatment with Radiation Therapy
A high impact study led by Daniel Spratt, MD, demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer.
Case Western Reserve University and UH Researchers Awarded Major Federal Grant to Study Esophagus Cancers
Researchers receive $11.2 million grant from the National Cancer Institute to learn about causes and treatments of esophagus cancers.
Bladder Cancer Expert, Known for her Medical Missions in Ukraine, Returns to University Hospitals Urology Institute and UH Seidman Cancer Center
Cleveland urologist returns to UH Urology Institute and UH Seidman Cancer Center after completing prestigious fellowship in urologic oncology. October mission to Ukraine will include two fellow UH urologists.
Collaboration in North Central Ohio Expands Specialized Oncology Care with UH Seidman Cancer Center
UH Seidman Cancer Center expands its reach to offer specialized care in Sandusky, Port Clinton, and Norwalk.
Study in journal Nature Communications finds high blood glucose levels sensitizes pancreatic cancer cells to chemotherapy
Researchers from University Hospitals Seidman Cancer Center and Case Western Reserve University see finding leading to potential adjunct agents for improved outcomes with chemo
New Study by UH Seidman Cancer Center Researchers and ArteraAI Published in NEJM Evidence
Study information validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.